Platelia *Aspergillus* Ag Assay

Bibliography Reference List: 298 References Published from 1998 to 2025

Since its launch in 1998, the Platelia *Aspergillus* Ag Assay has been the subject of a rich body of scientific and clinical research. This list presents the available articles and posters pertaining to the assay from its commercial launch up to September 2025.

The 298 references were found through Bio-Rad's Literature Search Process, an internal procedure that follows the guidelines set by the European Regulations (EU) 2017/746, using the Embase and MEDLINE databases.

The views and opinions expressed in these articles are those of the authors. Please note that **some articles focus on particular use cases—such as specific specimens, specific patient populations and different result interpretation rules—which are not validated or claimed by Bio-Rad** in the current IFU for Platelia *Aspergillus* Ag. **These use cases should therefore be considered with caution**.

This bibliography reference list is for informational purposes only and is not intended to provide medical advice or diagnosis. Because of intellectual property protections, Bio-Rad is unable to provide direct access to the articles in this reference list.

Articles

1. Aydın Kurc, M. et al. (2025). Invasive pulmonary aspergillosis evaluation in hematology patients: Three years results of tertiary hospital. Biomolecules & biomedicine, 25, 850–856.
2. Chen, C.-J. et al. (2025). Evaluation of Performance of the IMMY and Dynamiker *Aspergillus* Galactomannan lateral flow assays for the diagnosis of invasive Aspergillosis. Diagnostic Microbiology and Infectious Disease, 112.
3. Dubler, S. et al. (2025). Implications for the diagnosis of aspiration and aspergillosis in critically ill patients with detection of galactomannan in broncho-alveolar lavage fluids. Scientific reports, 15, 1997.
4. Haraguchi, M. et al. (2025). Refractory invasive pulmonary aspergillosis caused by two *Aspergillus* species in an allogeneic hematopoietic stem cell transplantation recipient. Journal of Infection and Chemotherapy, 31.
5. Kılıç, E. et al. (2025). Comparative Analysis of Chemiluminescence Immunoassay (CLIA)-Based Tests in the Diagnosis of Invasive Aspergillosis in Patients With Hematologic Malignancies. Mycoses, 68.
6. Lamberink, H. et al. (2025). Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease. Journal of Clinical Microbiology, 63.
7. Lee, R. et al. (2025). Rapid Differentiation of False Positives of Galactomannan Related to Contaminated Intravenous Fluids via a Pharmacokinetics Model and Innovative Web-Based Tool. Open Forum Infectious Diseases, 12, ofaf088.
8. Moussiegt, A. et al. (2025). Fungal biomarkers in HIV-associated disseminated histoplasmosis: a multicenter diagnostic accuracy study on the Guiana shield. International Journal of Infectious Diseases, Volume 153, 107360.

9. Pagliarone, M.J. et al. (2025). Is galactomannan a useful tool for triage and diagnosis of oral invasive aspergillosis? Hematology, Transfusion and Cell Therapy, 47.
10. Samaddar, A. et al. (2025). Evaluation of the Fujifilm Wako β-Glucan assay in cerebrospinal fluid for the diagnosis of non-cryptococcal fungal infections of the central nervous system. Diagnostic Microbiology and Infectious Disease, 113.
11. Schroeder, M. et al. (2025). Comparison of the Equivalence of *Aspergillus* Antigen and PCR Results Between Non-Directed Bronchial Lavage and Bronchoalveolar Lavage—A Prospective Exploratory Pilot Study in Critically Ill Patients. Mycoses, 68.
12. Wang, H. et al. (2025). Performance of mp-tNGS in Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis in Nonneutropenic Patients. Journal of Infectious Diseases, 231, 1609–1618.
13. Xu, C.-H. et al. (2025). Performance of Galactomannan, *Aspergillus*-PCR, and Metagenomic sequencing for the diagnosis of invasive pulmonary aspergillosis in hematological patients. Journal of Microbiology, Immunology and Infection [Preprint].
14. Acet-Öztürk NA et al. (2024). Impact of posaconazole prophylaxis and antifungal treatment on BAL GM performance in hematology malignancy patients with febrile neutropenia: a real-life experience. European Journal of Clinical Microbiology & Infectious Diseases 43, 33–43.
15. Aerts R et al. (2024). Microbiological diagnosis of pulmonary *Aspergillus* infections. Seminars in Respiratory and Critical Care Medicine 45, 021–031.
16. Ajayababu A et al. (2024). Effect of volume of instillate on the diagnostic utility of bronchoalveolar lavage galactomannan in patients with suspected chronic pulmonary aspergillosis—A pilot study. Mycoses 67, e13695.
17. Albert E et al. (2024). Comparative performance of the Platelia *Aspergillus* antigen and *Aspergillus* galactomannan antigen Virclia Monotest immunoassays in serum and lower respiratory tract specimens: a "real-life" experience. Microbiology Spectrum 12, e03910–23.
18. Bitterman, R. et al. (2024). Exhaled Breath Condensate Surveillance for *Aspergillus* in Acute Leukemia—a Pilot Trial. Open Forum Infectious Diseases, 11.
19. Boyer J et al. (2024). Performance of the clarus *Aspergillus* galactomannan enzyme immunoassay prototype for the diagnosis of invasive pulmonary aspergillosis in serum. Mycoses 67, e13756.
20. Charoonrochana, N. et al. (2024). A pilot study on nasal wash galactomannan as a surrogate marker for invasive aspergillosis among hematology patients in Thailand. Scientific reports, 14, 29383.
21. Chatterjee K et al. (2024). Utility of galactomannan diagnostic assay in rhino-orbito-cerebral mycosis in COVID-19 patients. Indian Journal of Medical Microbiology 48, 100557.
22. Chun JY et al. (2024). Performance of the galactomannan test for the diagnosis of invasive pulmonary aspergillosis using non-invasive proximal airway samples. Journal of Infection 88, 106159.
23. Conterno LO et al. (2024). Six-year experience with GM test in hematological patients in a public Brazilian tertiary hospital. The Brazilian Journal of Infectious Diseases 28, 103718.
24. Devillers E et al. (2024). Comparison of different lateral flow assays on bronchoalveolar lavage fluid for invasive aspergillosis screening in non-hematological patients. Journal of Medical Mycology 34, 101481.
25. van Grootveld R et al. (2024). Prospective and systematic screening for invasive aspergillosis in the ICU during the COVID-19 pandemic, a proof of principle for future pandemics. Medical Mycology 62, myae028.
26. Keche A et al. (2024). Galactomannan antigen assay for the diagnosis of invasive aspergillosis: a study from a tertiary care hospital of central India. Journal of Pure and Applied Microbiology 18, 878–885.
27. Küpper, C. et al. (2024). The *Aspergillus* galactomannan Ag VIRCLIA® Monotest and the sõna *Aspergillus* galactomannan lateral flow assay show comparable performance for the diagnosis of invasive aspergillosis. Mycoses, 67.
28. Liu, Z. et al. (2024). Metagenomic next-generation sequencing for the diagnosis of invasive pulmonary aspergillosis in type 2 diabetes mellitus patients.
29. Martins, S.C. et al. (2024). Comparison of galactomannan lateral flow assay and enzyme immunoassay to identify *Aspergillus* spp. in bronchoalveolar lavage fluid. Brazilian Journal of Infectious Diseases, 28.
30. Permpalung, N. et al. (2024). Invasive Fungal Infections in Inpatient Solid Organ Transplant Recipients With COVID-19: A Multicenter Retrospective Cohort. Transplantation, 108, 1613–1622.
31. Schub, T. et al. (2024). Serum antigen tests for the diagnosis of invasive aspergillosis: a retrospective comparison of five *Aspergillus* antigen assays and one beta-D-glucan assay. Journal of Clinical Microbiology, 62.
32. Solaimalai, D. et al. (2024). Diagnosis of invasive aspergillosis in haemato-oncology patients in a routine diagnostic setting. Medical Mycology, 62.

© 2026 Bio-Rad Laboratories, Inc.

33. dos Santos, A.P. et al. (2024). Performance of the IMMY® sona *Aspergillus* lateral flow assay for the detection of galactomannan in tracheal aspirate samples from Brazilian patients with COVID-19- associated pulmonary aspergillosis: Cross-sectional and systematic review of literature. Mycoses, 67.
34. Wang H et al. (2024). Performance of rapid on-site evaluation of touch imprints of bronchoscopic biopsies or lung tissue biopsies for the diagnosis of invasive pulmonary filamentous fungi infections in non-neutropenic patients. Journal of Clinical Microbiology 62, e0047924.
35. Wang W et al. (2024). Time-resolved fluoroimmunoassay for *Aspergillus* detection based on anti-galactomannan monoclonal antibody from stable cell line. Analytical Biochemistry 689, 115494.
36. Yu, T. et al. (2024). Examination of galactomannan levels in intraocular fluid to assist the diagnosis of *Aspergillus* endophthalmitis. Retina, 44, 1449–1455.
37. Aerts R et al. (2023). Implementation of lateral flow assays for the diagnosis of invasive aspergillosis in European hospitals: a survey from Belgium and a literature review of test performances in different patient populations. Mycopathologia 188, 655–665.
38. Alhan O et al. (2023). Diagnostic efficacy of *Aspergillus* galactomannan lateral flow assay in patients with hematological malignancies: a prospective multicenter study. Mycopathologia 188, 643–653.
39. Buil JB et al. (2023). Retrospective multicenter evaluation of the VirClia galactomannan antigen assay for the diagnosis of pulmonary aspergillosis with bronchoalveolar lavage fluid samples from patients with hematological disease. Journal of Clinical Microbiology 61, e0004423.
40. Chong E et al. (2023). False-positive *Aspergillus* galactomannan immunoassay in the glucose component of total parenteral nutrition products. Microbiology Spectrum 11, e0167323.
41. Chowdhury M et al. (2023). The utility of galactomannan and polymerase chain reaction assays in bronchoalveolar lavage for diagnosis of chronic pulmonary aspergillosis. Mycopathologia. 188, 1041–1053.
42. Das S et al. (2023). Diagnostic utility of galactomannan enzyme immunoassay in invasive aspergillosis in pediatric patients with hematological malignancy. Mycopathologia 188, 1055–1063.
43. Dichtl K et al. (2023). Performance of galactomannan testing from endotracheal aspirate to guide bronchoalveolar lavage in the diagnosis of invasive aspergillosis. Infection 51, 769–774.
44. Dubler Simon et al. (2023). Impact of invasive pulmonary aspergillosis in critically ill surgical patients with or without solid organ transplantation. Journal of Clinical Medicine 12, 3282.
45. Estella Á et al. (2023). Microbiological diagnosis of pulmonary invasive aspergillosis in critically ill patients with severe SARS-CoV-2 pneumonia: a bronchoalveolar study. Annals of Clinical Microbiology and Antimicrobials 22, 90. (Erratum in: (2023) Annals of Clinical Microbiology and Antimicrobials 9, 100).
46. Lass-Flörl C et al. (2023). A laboratory-based study on multiple biomarker testing in the diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA): real-life data. Diagnostics 13,114.
47. Mah J et al. (2023). Superior accuracy of *Aspergillus* plasma cell-free DNA polymerase chain reaction over serum galactomannan for the diagnosis of invasive aspergillosis. Clinical Infectious Diseases 77, 1282–1290.
48. de Oliveira VF et al. (2023). Sensitivity of antigen, serology, and microbiology assays for diagnosis of the subtypes of chronic pulmonary aspergillosis at a teaching hospital in São Paulo, Brazil. American Journal of Tropical Medicine and Hygiene 108, 22–26.
49. de Oliveira VF et al. (2023). Systematic review and meta-analysis of galactomannan antigen testing in serum and bronchoalveolar lavage for the diagnosis of chronic pulmonary aspergillosis: defining a cutoff. European Journal of Clinical Microbiology & Infectious Diseases 42, 1047–1054.
50. Pavone P et al. (2023). Active screening of COVID-19-associated pulmonary aspergillosis with serum beta-glucan and endotracheal aspirates galactomannan and fungal culture. Mycoses 66, 219–225.
51. Ren W et al. (2023). Serum cytokine biomarkers for use in diagnosing pulmonary tuberculosis versus chronic pulmonary aspergillosis. Infection and Drug Resistance 16, 2217–222.
52. Roiz-Mesones MP et al. (2023). Evaluation of the EUROIMMUN *Aspergillus* antigen immunoenzyme assay in serum and bronchoalveolar lavage fluid samples. Enfermedades Infecciosas y Microbiologia Clinica 41, 176–180.
53. Rothe K et al. (2023). Galactomannan-antigen testing from non-directed bronchial lavage for rapid detection of invasive pulmonary aspergillosis in critically ill patients: a proof-of-concept study. Diagnostics 13, 1190.
54. Sabbah R et al. (2023). Utility of galactomannan screening for early detection of invasive aspergillosis in high-risk hemato-oncology patients. Acta Haematologica 146, 358–365.

© 2026 Bio-Rad Laboratories, Inc.

55. Samantaray Subhashree et al. (2023). Invasive cerebral aspergillosis in non-neutropenic patients: a case series from Western India. Journal of Medical Mycology 33, 101380.

56. Sharad N et al. (2023). Therapeutic drug monitoring of voriconazole in children with hematologic malignancy and invasive fungal infections: an RCT study from a tertiary care centre in India. Cardiovascular & Hematological Disorders-Drug Targets 23, 285–292.

57. Shi Y et al. (2023). Metagenomic next-generation sequencing for detecting aspergillosis pneumonia in immunocompromised patients: a retrospective study. Frontiers in Cellular and Infection Microbiology 13, 1209724.

58. Shu F et al. (2023). Evaluation of the yeast phase-specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin sandwich ELISA to detect Talaromyces marneffei antigen in human urine. Frontiers in Cellular and Infection Microbiology 13, 1163868.

59. Zhou L et al. (2023). Diagnostic performance of noncultural methods for central nervous system aspergillosis. Mycoses 66, 308–316.

60. Zhou X et al. (2023). Risk factors and the value of microbiological examinations of COVID-19 associated pulmonary aspergillosis in critically ill patients in intensive care unit: the appropriate microbiological examinations are crucial for the timely diagnosis of CAPA. Frontiers in Cellular and Infection Microbiology 13, 1287496.

61. Zhu N et al. (2023). Performance of mNGS in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in non-neutropenic patients. Frontiers in Cellular and Infection Microbiology 13, 1271853.

62. Aerts R et al. (2022). Performance of the JF5-based galactomannoprotein EIA compared to the lateral flow device and the galactomannan EIA in serum and bronchoalveolar lavage fluid Journal of Clinical Microbiology 60, e0094822.

63. de Almeida JN et al. (2022). COVID-19-associated aspergillosis in a Brazilian referral centre: diagnosis, risk factors and outcomes. Mycoses 65, 449–457.

64. Bellanger AP et al. (2022). Investigation of the value of precipitins in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with a positive marker for *Aspergillus* species. Medical Mycology 60, myac031.

65. Bernardi RM et al. (2022). Evaluation of the diagnostic accuracy of galactomannan from the bronchoalveolar lavage fluid of patients with suspected invasive pulmonary aspergillosis. Revista Iberoamericana de Micología 39, 31–35.

66. Boyanova L (2022). Molecular and microbiological approaches for rapid etiological diagnosis of systemic mycoses. Problems of Infectious and Parasitic Diseases 49, 35–42.

67. Caggiano G et al. (2022). Tendency in pulmonary aspergillosis investigation during the COVID-19 era: What is changing? International Journal of Environmental Research and Public Health 19, 7079.

68. Calero AL et al. (2022). Comparison of the performance of two galactomannan detection tests: Platelia *Aspergillus* Ag and *Aspergillus* galactomannan Ag Virclia Monotest. Microbiology Spectrum 10, e02626–21.

69. Dargenio VN et al. (2022). An unexpected guest in a patient with ulcerative colitis. Gastroenterology 163, e1–e2.

70. Egger M et al. (2022). Performance of the Euroimmun *Aspergillus* Antigen ELISA for the diagnosis of invasive pulmonary aspergillosis in bronchoalveolar lavage fluid. Journal of Clinical Microbiology 60, e0021522.

71. Forster J et al. (2022). β-1,3-D-glucan and galactomannan as biomarkers for the detection of invasive Geotrichum and Magnusiomyces infections: a retrospective evaluation. Journal of Clinical Microbiology 60, e0160721.

72. Giusiano G et al. (2022). Usefulness of Sōna *Aspergillus* Galactomannan LFA with digital readout as diagnostic and as screening tool of COVID-19 associated pulmonary aspergillosis in critically ill patients. Data from a multicenter prospective study performed in Argentina. Medical Mycology 60, myac026.

73. Guo Y and Li J (2022). Sandwich-type homogeneous chemiluminescence immunoassay based on nanoparticle toward detection of *Aspergillus* galactomannan antigen. Talanta 243, 123392.

74. Hashim Z et al. (2022). Practice guidelines for the diagnosis of COVID-19-associated pulmonary aspergillosis in an intensive care setting. Journal of Intensive Care Medicine 37, 985–997.

75. Hernández-Solí A et al. (2022). Pulmonary aspergilloma in immunocompromised patients in a respiratory care unit. Journal of Infection in Developing Countries 16, 564–569.

76. Hsiao H-H et al. (2022). Comparison of a novel lateral-flow device to galactomannan assay at different time periods for detections of invasive aspergillosis. Journal of the Formosan Medical Association 121, 2123–2129.

77. McKinney WP et al. (2022). Performance of the IMMY® and OLM® lateral flow assays for *Aspergillus* galactomannan compared to fungal culture and Platelia™ galactomannan enzyme immuno-assay. New Zealand Journal of Medical Laboratory Science 76, 27–31.

© 2026 Bio-Rad Laboratories, Inc.

78. Melchers M et al. (2022). A 67-year-old male patient with COVID-19 with worsening respiratory function and acute kidney failure. Chest 161, e5–e11.

79. Swain S et al. (2022). COVID-19-associated subacute invasive pulmonary aspergillosis. Mycoses 65, 57–64.

80. Tschopp J et al. (2022). High false-positive rate of (1,3)-β-D-glucan in onco-hematological patients receiving immunoglobulins and therapeutic antibodies. Clinical Infectious Diseases 75, 330–333.

81. Xiao W et al. (2022). Existing tests vs. novel non-invasive assays for detection of invasive aspergillosis in patients with respiratory diseases. Chinese Medical Journal 135, 1545–1554.

82. Bellanger A-P et al. (2021). Investigating the impact of posaconazole prophylaxis on systematic fungal screening using galactomannan antigen, *Aspergillus* fumigatus qPCR, and Mucorales qPCR. Journal of Medical Mycology 31, 101117.

83. Busca A et al. (2021). Management of invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation: the Turin experience. Frontiers in Cellular and Infection Microbiology 11, 805514.

84. Chiu Y-Y et al. (2021). A rare patient with primary endogenous *Aspergillus* endophthalmitis. Journal of Microbiology, Immunology and Infection 54, 538–539.

85. Ergün M et al. (2021). *Aspergillus* test profiles and mortality in critically ill COVID-19 patients. Journal of Clinical Microbiology 59, e0122921.

86. Ghelfenstein-Ferreira T et al. (2021). Recovery of a triazole-resistant *Aspergillus* fumigatus in respiratory specimen of COVID-19 patient in ICU—A case report. Medical Mycology Case Reports 31, 15–18.

87. Haran A et al. (2021). False-positive galactomannan antigen testing in pulmonary nocardiosis. Medical Mycology 59, 206–209.

88. Hill JA et al. (2021). Liquid biopsy for invasive mold infections in hematopoietic cell transplant recipients with pneumonia through next-generation sequencing of microbial cell-free DNA in plasma. Clinical Infectious Diseases 73, e3876–e3883.

89. Hsu AJ et al. (2021). Challenges with utilizing the 1,3-Beta-D-glucan and galactomannan assays to diagnose invasive mold infections in immunocompromised children. Journal of Clinical Microbiology 59, e03276–20.

90. Huang L et al. (2021). Diagnostic value of galactomannan test in non-immunocompromised critically ill patients with influenza-associated aspergillosis: data from three consecutive influenza seasons. European Journal of Clinical Microbiology and Infectious Diseases 40, 1899–1907.

91. Lass-Flörl C et al. (2021). Serology anno 2021—fungal infections: from invasive to chronic. Clinical Microbiology and Infection 27, 1230–1241.

92. Mercier T et al. (2021). Defining galactomannan positivity in the updated EORTC/MSGERC consensus definitions of invasive fungal diseases. Clinical Infectious Diseases 72, S89–S94

93. Mercier T et al. (2021). Prospective evaluation of the turbidimetric β-D-glucan assay and 2 lateral flow assays on serum in invasive aspergillosis. Clinical Infectious Diseases 72, 1577–1584

94. Niyazi D et al. (2021). Invasive pulmonary aspergillosis in patients with haematological malignancies and hematopoietic stem cell transplantation: a single-center study. Folia medica 63, 941–947.

95. Oliva A et al. (2021). Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission. Infection 49, 965–975.

96. Roman-Montes CM et al. (2021). Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis. Mycoses 64, 364–371.

97. Rothe K et al. (2021). Clinical and microbiological features and outcomes of mucormycosis in critically ill patients. International Journal of Infectious Diseases 109, 142–147.

98. Schroeder I et al. (2021). Digestive enzymes of fungal origin as a relevant cause of false positive *Aspergillus* antigen testing in intensive care unit patients. Infection 49, 241–248.

99. Segrelles-Calvo G et al. (2021). Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia. Mycoses 64, 144–151.

100. Singh S et al. (2021). Comparative accuracy of 1,3 beta-D glucan and galactomannan for diagnosis of invasive fungal infections in pediatric patients: a systematic review with meta-analysis. Medical Mycology 59, 139–148.

101. Trujillo H et al. (2021). Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient. Transplant Infectious Disease 23, e13501.

102. Wei H et al. (2021). The values of (1,3)-β-D-glucan and galactomannan in cases of invasive fungal rhinosinusitis. American Journal of Otolaryngology—Head and Neck Medicine and Surgery 42, 102871.

© 2026 Bio-Rad Laboratories, Inc.

103. Wu Z et al. (2021). Diagnostic value of galactomannan in serum and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in non-neutropenic patients. Diagnostic Microbiology and Infectious Disease 99, 115274.

104. Ahamefula Osibe D et al. (2020). Cell wall polysaccharides from pathogenic fungi for diagnosis of fungal infectious disease. Mycoses 63, 644–652.

105. Bougnoux M-E et al. (2020). Impact of intravenous and subcutaneous immunoglobulins on false positivity of galactomannan and β-D-glucan antigenaemia and detection of circulating *Aspergillus* fumigatus DNA. Clinical Microbiology and Infection 26, 1101–1102.

106. Lee S-I et al. (2020). Usefulness of ICU criteria for diagnosis of invasive pulmonary aspergillosis in nonhematologic critically ill patients. Medical Mycology 58, 275–281.

107. Li X et al. (2020) Evaluation of quantitative real-time PCR and Platelia galactomannan assays for the diagnosis of disseminated Talaromyces marneffei infection. Medical Mycology 58, 181–186.

108. Liu W-D et al. (2020). False-positive *Aspergillus* galactomannan immunoassays associated with intravenous human immunoglobulin administration. Clinical Microbiology and Infection 26, 1555.e9–1555.e14.

109. Mercier T et al. (2020). Point of care *Aspergillus* testing in intensive care patients. Critical Care 24, 642.

110. Nasir N et al. (2020). COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. Mycoses 63, 766–770.

111. Nyga R et al. (2020). Invasive tracheobronchial aspergillosis in critically ill patients with severe influenza. A clinical trial. American Journal of Respiratory and Critical Care Medicine 202, 708–716.

112. Patel R et al. (2020). A unique case of disseminated histoplasmosis misdiagnosed as invasive aspergillosis. Chest 158, A367–A368.

113. Sarwar M et al. (2020). Evaluation of galactomannan and beta-d-glucan assays for the diagnosis of invasive aspergillosis in clinically suspected cases. Journal of the Pakistan Medical Association 70, 442–446.

114. Schein F et al. (2020). Fatal aspergillosis complicating severe SARS-CoV-2 infection: a case report. Journal de Mycologie Médicale 30, 101039.

115. Taton O et al. (2020). Role of the bronchoalveolar lavage in noncritically ill patients during the SARS-CoV-2 epidemic. Pulmonary Medicine 2020, 9012187.

116. Dichtl K et al. (2019). Evaluation of a novel *Aspergillus* antigen enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 57, e00136–19.

117. Jenks JD et al. (2019). Bronchoalveolar lavage *Aspergillus* galactomannan lateral flow assay versus *Aspergillus*-specific lateral flow device test for diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies. Journal of Infection 78, 249–259.

118. Jenks JD et al. (2019). Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: *Aspergillus* galactomannan lateral flow assay versus *Aspergillus*-specific lateral flow device test in bronchoalveolar lavage. Mycoses 62, 230–236.

119. Khaithir TMN et al. (2019). Epidemiology, laboratory detection and distribution of *Aspergillus* species from clinical samples in a tertiary medical centre from Malaysia. International Medical Journal 26, 483–486.

120. Ortiz-Brizuela E et al. (2019). False-positive results in the galactomannan Platelia™ *Aspergillus* assay with generic piperacillin/tazobactam. Revista Iberoamericana de Micologia 36, 51–52.

121. Takazono T et al. (2019). Clinical features and cause analysis of false positive results of *Aspergillus* galactomannan assay in pulmonary cryptococcosis patients. European Journal of Clinical Microbiology and Infectious Diseases 38, 735–741.

122. Wang X et al. (2019). Utility of serum galactomannan antigen testing combined with chest computed tomography for early diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies with febrile neutropenia after antifungal drug treatment. Journal of International Medical Research 47, 783–790.

123. Abe Y et al. (2018). Prevalence and clinical characteristics of false-positive *Aspergillus* galactomannan test in healthy subjects and patients with hematologic malignancies. Blood 132 (Supplement 1), 2408.

124. Moura S et al. (2018). Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach. European Journal of Clinical Microbiology and Infectious Diseases 37, 1393–1403.

125. Roohani A et al. (2018). Comparing the profile of respiratory fungal pathogens amongst immunocompetent and immunocompromised hosts, their susceptibility pattern and correlation of various opportunistic respiratory fungal infections and their progression in relation to the CD4+T-cell counts. Indian Journal of Medical Microbiology 36, 408–415.

126. Singh S et al. (2018). Evaluation of biomarkers: galactomannan and 1,3-beta-D-glucan assay for the diagnosis of invasive fungal infections in immunocompromised patients from a tertiary care centre. Indian Journal of Medical Microbiology 36, 557–563.

© 2026 Bio-Rad Laboratories, Inc.

127. Vrioni G et al. (2018). Use of galactomannan antigen and *Aspergillus* DNA real-time polymerase chain reaction as routine methods for invasive aspergillosis in immunosuppressed children in Greece. Clinical Therapeutics. 40, 918–924.e2.

128. Yoshimura K et al. (2018). Utility of serum *Aspergillus*-galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease. PLoS ONE 13, e0198479.

129. Alanio A et al. (2017). Circulating *Aspergillus* fumigatus DNA is quantitatively correlated to galactomannan in serum. Frontiers in Microbiology 8, 2040.

130. Kaur R et al. (2017). Fungal opportunistic pneumonias in HIV/AIDS patients: an Indian tertiary care experience. Journal of Clinical and Diagnostic Research 11, DC14–DC19.

131. Ramanan P et al. (2017). Laboratory diagnostics for fungal infections: a review of current and future diagnostic assays. Clinics in Chest Medicine 38, 535–554.

132. Weinbergerova B et al. (2017). Serological approaches. Methods in Molecular Biology 1508, 209–221.

133. White PL et al. (2017). An evaluation of the performance of the Dynamiker® Fungus (1-3)-β-D-Glucan Assay to assist in the diagnosis of invasive aspergillosis, invasive candidiasis and Pneumocystis pneumonia. Medical Mycology 55, 843–850.

134. Badiee P et al. (2016). Non-invasive methods to diagnose fungal infections in pediatric patients with hematologic disorders. Jundishapur Journal of Microbiology 9, e41573.

135. Boch T et al. (2016). Direct comparison of galactomannan performance in concurrent serum and bronchoalveolar lavage samples in immunocompromised patients at risk for invasive pulmonary aspergillosis. Mycoses 59, 80–85.

136. Erdmann J-H et al. (2016). Anti-*Aspergillus* immunoglobulin-G testing in serum of hematopoietic stem cell transplant recipients. Transplant Infectious Disease 18, 354–360.

137. Knoth H et al. (2016). In-vitro detection of mannan and galactomannan in components of total parenteral nutrition (TPN). Pharmazie 71, 238–242.

138. Li M-C et al. (2016). Diagnostic role of an oligonucleotide array in a heart transplantation patient with invasive pulmonary aspergillosis. Journal of Microbiology, Immunology and Infection 49, 817–818.

139. Prattes J et al. (2016). Point of care testing for the diagnosis of fungal infections: are we there yet? Current Fungal Infection Reports 10, 43–50.

140. Agarwal R et al. (2015). Performance of serum galactomannan in patients with allergic bronchopulmonary aspergillosis. Mycoses 58, 408–412.

141. de Azevedo PZ et al. (2015). Evaluation of the double agar gel immunodiffusion test and of the enzyme-linked immunosorbent assay in the diagnosis and follow-up of patients with chronic pulmonary aspergillosis. PLoS ONE 10, e0134841.

142. Bellanger AP et al. (2015). Combining *Aspergillus* mitochondrial and ribosomal QPCR, in addition to galactomannan assay, for early diagnosis of invasive aspergillosis in hematology patients. Medical Mycology 53, 760–764.

143. Gorton RL et al. (2015). Improved standardization of the Bio-Rad Platelia *Aspergillus* galactomannan antigen sandwich enzyme immunoassay using the DS2 (Dynex) enzyme-linked immunosorbent assay (ELISA) processing system. Journal of Clinical Microbiology 53, 2072–2078.

144. Guigue N et al. (2015). Importance of operational factors in the reproducibility of *Aspergillus* galactomannan enzyme immune assay. PLoS ONE 10, e0124044.

145. Mikulska M et al. (2015). Non-cultural methods for the diagnosis of invasive fungal disease. Expert Review of Anti-Infective Therapy 13, 103–117.

146. Roiz MP et al. (2015). Repeating the Platelia™ *Aspergillus* test in samples positive for serum galactomannan: is it necessary? Revista Iberoamericana de Micologia 32, 204–207.

147. Wang Y-F et al. (2015). Serological surveillance for Penicillium marneffei infection in HIV-infected patients during 2004-2011 in Guangzhou, China. Clinical Microbiology and Infection 21, 484–489.

148. Zheng J et al. (2015). A clinical study of acquired immunodeficiency syndrome associated Penicillium marneffei infection from a non-endemic area in China. PLoS ONE 10, e0130376.

149. Badiee P et al. (2014). Evaluation of noninvasive methods for the diagnosis of fungal endocarditis. Medical Mycology 52, 528–534.

150. Gazzoni FF et al. (2014). High-resolution computed tomographic findings of *Aspergillus* infection in lung transplant patients. European Journal of Radiology 83, 79–83.

151. Griffin AT and Hanson KE (2014). Update on fungal diagnostics. Current Infectious Disease Reports 16, 415.

152. Lamoth F and Alexander BD (2014). Nonmolecular methods for the diagnosis of respiratory fungal infections. Clinics in Laboratory Medicine 34, 315–336.

153. Lin J-C et al. (2014). Evaluation of galactomannan enzyme immunoassay and quantitative real-time PCR for the diagnosis of invasive pulmonary aspergillosis in a rat model. Journal of Microbiology and Biotechnology 24, 1044–1050.

© 2026 Bio-Rad Laboratories, Inc.

154. Nucci M et al. (2014). Earlier diagnosis of invasive fusariosis with *Aspergillus* serum galactomannan testing. PLoS ONE 9, e87784.

155. Sulahian A et al. (2014). Use and limits of (1-3)-β-D-glucan assay (Fungitell), compared to galactomannan determination (Platelia *Aspergillus*), for diagnosis of invasive aspergillosis. Journal of Clinical Microbiology 52, 2328–2333.

156. Vergidis P et al. (2014). Reduction in false-positive *Aspergillus* serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. Journal of Clinical Microbiology 52, 2199–2201.

157. Virginio ED et al. (2014). Immunoproteome of *Aspergillus* fumigatus using sera of patients with invasive aspergillosis. International Journal of Molecular Sciences 15, 14505–14530.

158. Wang L et al. (2014). Retrospective comparison of nucleic acid sequence-based amplification, real-time PCR, and galactomannan test for diagnosis of invasive aspergillosis. Journal of Molecular Diagnostics 16, 584–590.

159. Held J et al. (2013). Comparison of a novel *Aspergillus* lateral-flow device and the Platelia® galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection 41, 1163–1169.

160. Lackner M and Lass-Flörl C (2013). Up-date on diagnostic strategies of invasive aspergillosis. Current Pharmaceutical Design 19, 3595–3614.

161. Lindsley MD (2013). The future of fungal serology. Current Fungal Infection Reports 7, 161–170.

162. Morrissey CO et al. (2013). Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. The Lancet Infectious Diseases 13, 519–528.

163. Nabili M et al. (2013). Detection of invasive aspergillosis in bone marrow transplant recipients using real-time PCR. Journal of Global Infectious Diseases 5, 68–75.

164. Richaud C et al. (2013). Fungal infections associated with travel. Current Fungal Infection Reports 7, 311–319.

165. Schwarzinger M et al. (2013). Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. PLoS ONE 8, e65776.

166. Steinbach WJ (2013). Are we there yet? Recent progress in the molecular diagnosis and novel antifungal targeting of *Aspergillus* fumigatus and invasive aspergillosis. PLoS Pathogens 9, e1003642.

167. Trabelsi H et al. (2013). Invasive fungal infections in renal transplant recipients: about 11 cases. Journal de Mycologie Médicale 23, 255–260.

168. Badiee P et al. (2012). Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. Journal of Infection in Developing Countries 6, 352–357.

169. Bizzini A et al. (2012). Response to: Lack of intra-laboratory reproducibility in using Platelia *Aspergillus* enzyme immunoassay test for detection of *Aspergillus* galactomannan antigen. Transplant Infectious Disease 14, 218–219.

170. D'Haese J et al. (2012). Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. Journal of Clinical Microbiology 50, 1258–1263.

171. Fontana C et al. (2012). (1-3)-β-D-glucan vs galactomannan antigen in diagnosing invasive fungal infections (IFIs). Open Microbiology Journal 6, 70–73.

172. Izumikawa K et al. (2012). Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Medical Mycology 87, 811–817.

173. Metan G et al. (2012). Does ampicillin-sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. Mycoses 55, 366–371.

174. Nabili M et al. (2012). [Evaluation of galactomannan assay in serum for detection of invasive aspergillosis in patients with hematologic malignancies and bone marrow transplant recipients]. Journal of Mazandaran University of Medical Sciences 22, 9–19. (Persian)

175. Oren I et al. (2012). Lack of intra-laboratory reproducibility in using Platelia *Aspergillus* enzyme immunoassay test for detection of *Aspergillus* galactomannan antigen. Transplant Infectious Disease 14, 107–109.

176. Stopiglia CDO et al. (2012). Standardization and characterization of antigens for the diagnosis of aspergillosis. Canadian Journal of Microbiology 58, 455–462.

177. Tănase AD et al. (2012). Using the galactomannan antigen assay in the diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Romanian Journal of Morphology and Embryology 53, 379–382.

178. Thornton C et al. (2012). Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. Journal of visualized experiments: JoVE, 3721.

© 2026 Bio-Rad Laboratories, Inc.

179. Van Der Veer J et al. (2012). Cross-reactivity in the Platelia™ *Aspergillus* enzyme immunoassay caused by blastomycosis. Medical Mycology 50, 396–398.

180. Warren TA et al. (2012). Serum galactomannan in cystic fibrosis patients colonized with *Aspergillus* species. Medical Mycology 50, 658–660.

181. Aydoğan S et al. (2010). [Comparison of glucan and galactomannan tests with real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model]. Mikrobiyoloji bülteni 44, 441–452. (Turkish)

182. Gao X et al. (2010). Invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease and the diagnostic value of combined serological tests. Annals of Saudi Medicine 30, 193–197.

183. Metan G et al. (2010). The interaction between piperacillin/tazobactam and assays for *Aspergillus* galactomannan and 1,3-beta-d-glucan in patients without risk factors for invasive fungal infections. Infection 38, 217–221.

184. Millon L et al. (2010). False-positive *Aspergillus* real-time PCR assay due to a nutritional supplement in a bone marrow transplant recipient with GVH disease. Medical Mycology 48, 661–664.

185. Paugam A et al. (2010). Diagnosis of invasive pulmonary aspergillosis: value of bronchoalveolar lavage galactomannan for immunocompromised patients. Pathologie Biologie 58, 100–103.

186. Racil Z et al. (2010). Mucositis does not lead to false-positivity of the Platelia *Aspergillus* enzyme-linked immunosorbent assay. European Journal of Clinical Microbiology and Infectious Diseases 29, 851–855.

187. Thornton CR (2010). Detection of invasive aspergillosis. Advances in Applied Microbiology 70, 187–216.

188. Kitasato Y et al. (2009). Comparison of *Aspergillus* galactomannan antigen testing with a new cut-off index and *Aspergillus* precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology 14, 701–708.

189. Luong M et al. (2009). *Aspergillus* galactomannan antigen in bronchoalveolar lavage (BAL) from haematology oncology patients: time for a change in index cut-off value. International Journal of Antimicrobial Agents 34, S15–S16.

190. Maertens J et al. (2009). Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clinical Infectious Diseases 49, 1688–1693.

191. Sun Q-X et al. (2009). [Utility of serum galactomannan in diagnosis of invasive fungal infection in hematologic malignancy]. Chinese Journal of Infection and Chemotherapy 9, 140–142. (Chinese)

192. Xu M-Z et al. (2009). [Utility of serum galactomannan antigen for diagnosis and follow-up of invasive aspergillosis in hematological patients]. Chinese Journal of Infection and Chemotherapy 9, 233–236. (Chinese)

193. Yao JF et al. (2009). [A preliminary investigation on early diagnosis of invasive aspergillosis in patients with blood diseases by using circulating galactomannan test]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17, 765–769. (Chinese)

194. Yao JF et al. (2009). [Circulating galactomannan screening for early diagnosis and treatment of invasive aspergillosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 30, 592–595. (Chinese)

195. Hao W et al. (2008). Well-characterized monoclonal antibodies against cell wall antigen of *Aspergillus* species improve immunoassay specificity and sensitivity. Clinical and Vaccine Immunology 15, 194–202.

196. Husain S et al. (2008). Performance characteristics of the Platelia *Aspergillus* enzyme immunoassay for detection of *Aspergillus* galactomannan antigen in bronchoalveolar lavage fluid. Clinical and Vaccine Immunology 15, 1760–1763.

197. Mennink-Kersten MASH et al. (2008). Improved detection of circulating *Aspergillus* antigen by use of a modified pretreatment procedure. Journal of Clinical Microbiology 46, 1391–1397.

198. Penack O et al. (2008). *Aspergillus* galactomannan testing in patients with long-term neutropenia: implications for clinical management. Annals of Oncology 19, 984–989.

199. Penack O et al. (2008). False-positive *Aspergillus* antigen testing due to application of piperacillin/tazobactam—is it still an issue? Diagnostic Microbiology and Infectious Disease 60, 117–120.

200. Zandijk E et al. (2008). False-positive results by the Platelia *Aspergillus* galactomannan antigen test for patients treated with amoxicillin-clavulanate. Clinical and Vaccine Immunology 15, 1132–1133.

201. Ahmad S et al. (2007). Diagnostic value of DNA, (1-3)-β-d-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with *Aspergillus* terreus. Diagnostic Microbiology and Infectious Disease 59, 165–171.

202. De Jesus M et al. (2007). Galactoxylomannan does not exhibit cross-reactivity in the Platelia *Aspergillus* enzyme immunoassay. Clinical and Vaccine Immunology 14, 624–627.

203. Hage CA et al. (2007). Plasmalyte as a cause of false-positive results for *Aspergillus* galactomannan in bronchoalveolar lavage fluid. Journal of Clinical Microbiology 45, 676–677.

© 2026 Bio-Rad Laboratories, Inc.

204. Huang YT et al. (2007). Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. Journal of Clinical Microbiology 45, 2858–2862.

205. Husain S et al. (2007). *Aspergillus* galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 83, 1330–1336.

206. Lai CC et al. (2007). Assessment of Platelia *Aspergillus* enzyme immunoassay for the diagnosis of invasive aspergillosis. Journal of Microbiology, Immunology and Infection 40, 148–153.

207. Lim ZY et al. (2007). False positive results of galactomannan ELISA assay in haemato-oncology patients: a single centre experience. Journal of Infection 55, 201–202.

208. Maertens J et al. (2007). Optimization of the cutoff value for the *Aspergillus* double-sandwich enzyme immunoassay. Clinical Infectious Diseases 44, 1329–1336.

209. Nataloni S et al. (2007). Successful early voriconazole treatment of *Aspergillus* infection in two non immunocompromised patients in Intensive Care Unit. Minerva Anestesiologica 73, 371–375.

210. Ranque S et al. (2007). Platelia *Aspergillus* assay for diagnosis of disseminated histoplasmosis. European Journal of Clinical Microbiology and Infectious Diseases 26, 941–943.

211. Wheat LJ et al. (2007). Histoplasmosis-associated cross-reactivity in the Bio-Rad Platelia *Aspergillus* enzyme immunoassay. Clinical and Vaccine Immunology 14, 638–640.

212. Woods G et al. (2007). Serum *Aspergillus* galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 110, 830–834.

213. Yücesoy M and Ergon MC (2007). [Investigation of *Aspergillus* galactomannan levels in antimicrobial agents]. Mikrobiyoloji bülteni 41, 565–570. (Turkish)

214. Alexander BD and Pfaller MA (2006). Contemporary tools for the diagnosis and management of invasive mycoses. Clinical Infectious Diseases 43, S15–S27.

215. Aubry A et al. (2006). Occurrence and kinetics of false-positive *Aspergillus* galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. Journal of Clinical Microbiology 44, 389–394.

216. Maertens J et al. (2006). Defining a case of invasive aspergillosis by serum galactomannan. Medical Mycology 44, 173–178.

217. Mennink-Kersten MASH et al. (2006). In vitro release by *Aspergillus* fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. Journal of Clinical Microbiology 44, 1711–1718.

218. Rex JH (2006). Galactomannan and the diagnosis of invasive aspergillosis. Clinical Infectious Diseases 42, 1428–1430.

219. Roilides E (2006). Early diagnosis of invasive aspergillosis in infants and children. Medical Mycology 44, 199–205.

220. Verweij PE and Mennink-Kersten MASH (2006). Issues with galactomannan testing. Medical Mycology 44, 179–183.

221. Allan EK et al. (2005). Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. British Journal of Haematology 128, 578–579.

222. Bart-Delabesse E et al. (2005). Detection of *Aspergillus* galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. Journal of Clinical Microbiology 43, 5214–5220.

223. Hope WW et al. (2005). Laboratory diagnosis of invasive aspergillosis. Lancet Infectious Diseases 5, 609–622.

224. Ide L et al. (2005). A case of *Aspergillus* fumigatus peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD): diagnostic and therapeutic challenges. Journal of Clinical Pathology 58, 559.

225. Joseph Wheat L (2005). Galactomannan antigenemia detection for diagnosis of invasive aspergillosis, part II. Clinical Microbiology Newsletter 27, 59–63.

226. Labadaridis I et al. (2005). Chitotriosidase in neonates with fungal and bacterial infections. Archives of Disease in Childhood: Fetal and Neonatal Edition 90, F531–F532.

227. Pazos C et al. (2005). [Contribution of (1→3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan]. Journal of Clinical Microbiology 43, 299–305. (Spanish)

228. Pereira CN et al. (2005). The contribution of galactomannan detection in the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Mycopathologia 159, 487–493.

229. Scotter JM et al. (2005). Comparison of PCR-ELISA and galactomannan detection for the diagnosis of invasive aspergillosis. Pathology 37, 246–253.

230. Wheat LJ (2005). Galactomannan antigenemia detection for diagnosis of invasive aspergillosis, part I. Clinical Microbiology Newsletter 27, 51–57.

© 2026 Bio-Rad Laboratories, Inc.

231. Zaas AK and Alexander BD (2005). Galactomannan and advances in fungal diagnostics. Current Opinion in Organ Transplantation 10, 307–311.

232. Husain S et al. (2004). Prospective assessment of Platelia *Aspergillus* galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. American Journal of Transplantation 4, 796–802.

233. Klont RR et al. (2004). Utility of *Aspergillus* antigen detection in specimens other than serum specimens. Clinical Infectious Diseases 39, 1467–1474.

234. Kwak EJ et al. (2004). Efficacy of galactomannan antigen in the Platelia *Aspergillus* enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. Journal of Clinical Microbiology 42, 435–438.

235. Maertens J et al. (2004). Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. British Journal of Haematology 126, 852–860.

236. Mennink-Kersten MASH et al. (2004). Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infectious Diseases 4, 349–357.

237. Singh N et al. (2004). Reactivity of Platelia *Aspergillus* galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrobial Agents and Chemotherapy 48, 1989–1992.

238. Willinger B (2004). [Antigen detection in invasive aspergillosis and candidosis: the Austrian experience]. Mycoses, Supplement 47, 48–54. (German)

239. Jarque I et al. (2003). [Value of *Aspergillus* galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patients]. Revista Iberoamericana de Micologia 20, 116–118. (Spanish)

240. Lombardi G et al. (2003). Multicenter evaluation of an enzyme immunoassay (Platelia *Aspergillus*) for the detection of *Aspergillus* antigen in serum. Mycopathologia 155, 129–133.

241. Meletiadis J et al. (2003). Evaluation of a polymerase chain reaction reverse hybridization line probe assay for the detection and identification of medically important fungi in bronchoalveolar lavage fluids. Medical Mycology 41, 65–74.

242. Moragues MD et al. (2003). [Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis]. Revista Iberoamericana de Micologia 20, 103–110. (Spanish)

243. del Palacio A et al. (2003). [Laboratory diagnosis of invasive aspergillosis]. Revista Iberoamericana de Micologia 20, 90–98. (Spanish)

244. del Palacio A et al. (2003). [Invasive aspergillosis]. Revista Iberoamericana de Micologia 20, 77–78. (Spanish)

245. Pazos C and del Palacio A (2003). [Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by Platelia *Aspergillus*]. Revista Iberoamericana de Micologia 20, 99–102. (Spanish)

246. Pinel C et al. (2003). Detection of circulating *Aspergillus* fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. Journal of Clinical Microbiology 41, 2184–2186.

247. Rovira Tarrats M and De La Bellacasa JP (2003). [*Aspergillus* galactomannan detection in allogeneic hematopoietic cell transplantation]. Revista Iberoamericana de Micologia 20, 111–115. (Spanish)

248. Sulahian A et al. (2003). False positive test for *Aspergillus* antigenemia related to concomitant administration of piperacillin and tazobactam. New England Journal of Medicine 349, 2366–2367.

249. Wheat LJ (2003). Rapid diagnosis of invasive aspergillosis by antigen detection. Transplant Infectious Disease 5, 158–166.

250. Centeno-Lima S et al. (2002). Follow-up of anti-*Aspergillus* IgG and IgA antibodies in bone marrow transplanted patients with invasive aspergillosis. Journal of Clinical Laboratory Analysis 16, 156–162.

251. Doermann F et al. (2002). [Evaluation of *Aspergillus* antigen detection in sera by ELISA for diagnosis of invasive aspergillosis in a hematological unit]. Journal de Mycologie Médicale 12, 131–135. (French)

252. Cuenca-Estrella M and Rodríguez-Tudela JL (2001). Critical assessment of issues in the diagnosis of invasive aspergillosis. Clinical Microbiology and Infection 7, 32–37.

253. Fortun J et al. (2001). *Aspergillus* antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 71, 145–149.

254. Hamaki T et al. (2001). False-positive results of *Aspergillus* enzyme-linked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplantation 28, 633–634.

255. Siemann M and Koch-Dörfler M (2001). The Platelia *Aspergillus* ELISA in diagnosis of invasive pulmonary aspergillosis (IPA). Mycoses 44, 266–272.

© 2026 Bio-Rad Laboratories, Inc.

256. Sulahian A et al. (2001). Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91, 311–318.

257. Tollemar J et al. (2001). Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clinical Microbiology and Infection 7, 54–61.

258. Buchheidt D et al. (2000). Systemic infections with Candida sp. and *Aspergillus* sp. in immunocompromised patients with hematological malignancies: current serological and molecular diagnostic methods. Chemotherapy 46, 219–228.

259. Machetti M et al. (2000). Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transplant Infectious Disease 2, 140–144.

260. Salonen J et al. (2000). *Aspergillus* antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scandinavian Journal of Infectious Diseases 32, 485–490.

261. Verweij PE et al. (2000). Failure to detect circulating *Aspergillus* markers in a patient with chronic granulomatous disease and invasive aspergillosis. Journal of Clinical Microbiology 38, 3900–3901.

262. Williamson EC et al. (2000). *Aspergillus* antigen testing in bone marrow transplant recipients. Journal of Clinical Pathology 53, 362–366.

263. Costes B et al. (1999). Lack of evidence of heterozygosity for cystic fibrosis as a risk factor for invasive aspergillosis in haematological patients. European Journal of Clinical Microbiology and Infectious Diseases 18, 677–678.

264. Kawamura S et al. (1999). Comparison between PCR and detection of antigen in sera for diagnosis of pulmonary aspergillosis. Journal of Clinical Microbiology 37, 218–220.

265. Letscher-Bru V et al. (1998). [*Aspergillus* galactomannan antigen detection with Platelia *Aspergillus*: multiple positive antigenemia without *Aspergillus* infection]. Journal de Mycologie Médicale 8, 112–113. (French)

266. Machetti M et al. (1998). Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplantation 21, 917–921.

267. Siemann M et al. (1998). False-positive results in premature infants with the Platelia *Aspergillus* sandwich enzyme-linked immunosorbent assay. Mycoses 41, 373–377.

268. Verweij PE et al. (1998). Detection of antigen in sera of patients with invasive aspergillosis: intra- and interlaboratory reproducibility. Journal of Clinical Microbiology 36, 1612–1616.

Posters

269. Aerts R et al. (2022). QuickGM *Aspergillus* galactomannan Ag lateral flow assay as a practical aid to diagnose invasive aspergillosis in high-risk hematology patients. Medical Mycology 60, 244–245. P412. http://dx.doi.org/10.1093/mmy/ myac072.P412

270. Padaki P et al. (2022). A study to compare detection of *Aspergillus* galactomannan in patients with clinically suspected invasive aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria. Medical Mycology 60, 259–260. P436. http://dx.doi.org/10.1093/mmy/ myac072.P436

271. Singh S et al. (2022). Evaluation of fungal serum biomarkers in the diagnosis and for monitoring patients with post tuberculosis chronic pulmonary aspergillosis. Medical Mycology 60, 242. P408. http://dx.doi.org/10.1093/mmy/ myac072.P408

272. Ono A et al. (2020). [The clinical and immunological features of NMO patients with onset over 80 years old]. Clinical Neurology 60, S371. https://doi.org/10.5692/clinicalneurol.60_supplement_S371 (Japanese)

273. Farooqi JQ et al. (2017). Utility of (1-3)-β-D-glucan and galactomannan for invasive fungal infections at Aga Khan University Clinical Laboratory, Karachi. Mycoses 60, 120–121. P002. https://doi.org/10.1111/myc.12674

274. Simon M et al. (2017). Pretreatment of respiratory specimens with Liquillizer™ does not impair the detection of galactomannan antigen in contrast to other mucolytic agents. Mycoses 60, 25–26. P09. http://dx.doi.org/10.1111/myc.12659

275. Tryliska T et al. (2017). Galactomannan antigen detection for the diagnostics and monitoring of the efficacy of invasive aspergillosis treatment: experience with the method in pediatric patients. Clinical Chemistry and Laboratory Medicine 55, S929. W121. http://dx.doi.org/10.1515/cclm-2017-5026

276. Yu W-L (2017). Epidemiological correlation of PM2.5 with invasive pulmonary aspergillosis in severe influenza patients. International Journal of Antimicrobial Agents 50, Supplement 2, S193–S194. PS 335. https://doi.org/10.1016/S0924-8579(17)30423-5

277. Findik D et al. (2015). Combination of galactomannan detection and computed tomographic findings for diagnosis of invasive pulmonary aspergillosis. Mycoses 58, 97–98. P128. http://dx.doi.org/10.1111/myc.12380

© 2026 Bio-Rad Laboratories, Inc.

278. Ignatyeva SM et al. (2015). Galactomannan determination in biological samples of non-hematological patients with invasive aspergillosis caused by different *Aspergillus* spp. Mycoses 58, 107. P147. http://dx.doi.org/10.1111/myc.12380

279. Tran VH et al. (2015). Survey of serum *Aspergillus* antigen in patients undergoing chemotherapy for acute myeloid leukemia or allogeneic hematopoietic stem cell transplantation: role in predicting invasive aspergillosis and in modifying the therapeutic strategy. Blood 126, 3428. https://doi.org/10.1182/blood.V126.23.3428.3428

280. Binder U et al. (2013). Influence of hypoxia on antifungal susceptibility, sterol pattern and biomarker release of *Aspergillus* spp. Mycoses 56, 62. P014. http://dx.doi.org/10.1111/myc.12124

281. Golas M et al. (2013). Quantitative galactomannan detection in comparison to real-time PCR method in diagnosing invasive aspergillosis. Mycoses 56, 74–75. P052. http://dx.doi. org/10.1111/myc.12124

282. Keceli S et al. (2013). Correlation of galactomannan antigen levels with neutrophil counts and iNOS activity in hematogical patients at high risk for invasive aspergillosis. Mycoses 56, 116. P172. http://dx.doi.org/10.1111/myc.12124

283. Persat F (2013). New *Aspergillus* antigen detection LFD kit for the IPA diagnostic: what results with positive and negative galactomannan ELISA sera? Mycoses 56, 85–86. P077. http://dx.doi.org/10.1111/myc.12124

284. Beck J et al. (2012). Characterization of chitosanase B of *Aspergillus* fumigatus and evaluation of its potential use as an antigen in serological diagnostics. Mycoses 55, 182. P281. http://dx.doi.org/10.1111/j.1439-0507.2012.02206.x

285. Delfino E et al. (2012). Sputum galactomannan in cystic fibrosis patients colonized with *Aspergillus* fumigatus. Pediatric Pulmonology 47, 341. P330. http://dx.doi.org/10.1002/ppul.22682

286. Persat F et al. (2012). External quality assessment scheme and interlaboratory proficiency testing for *Aspergillus* galactomannan ELISA. Mycoses 55, 272. P562. http://dx.doi. org/10.1111/j.1439-0507.2012.02206.x

287. Rath PM et al. (2012). Detection of *Aspergillus* fumigatus-DNA in blood by a commerically available mutiplex-PCR. Mycoses 55, 295. P637. http://dx.doi.org/10.1111/j.1439-0507.2012.02206.x

288. Yebra E et al. (2012). Utility of galactomannan enzyme immunoassay, (1-3) β-D-glucan assay and anti-Candida albicans germ tube antibodies in invasive fungal disease in patients with hematologic malignancies. Mycoses 55, 288–289. P613. http://dx.doi.org/10.1111/j.1439-0507.2012.02206.x

289. Berry L et al. (2011). The use of galactomannan detection in urine samples from haemato-oncology patients at high risk of invasive aspergillosis. Clinical Microbiology and Infection 17, S632–S633. P355. http://dx.doi.org/10.1111/j.1469-0691.2011.03558.x

290. Khan Z et al. (2011). Development of an inhalation model of invasive pulmonary aspergillosis by *Aspergillus* fumigatus for evaluating the efficacy of detection of non-invasive markers for early diagnosis of infection. Clinical Microbiology and Infection 17, S568. P1939. http://dx.doi.org/10.1111/j.1469-0691.2011.03558.x

291. Nawrot U et al. (2011). Diagnostic pitfalls in *Aspergillus* galactomannan blood testing in the diagnosis of invasive fungal diseases in pediatric patients after hematopoietic stem cell transplantation. Mycoses 54, 102–103. http://dx.doi. org/10.1111/j.1439-0507.2011.02092.x

292. Roselló E et al. (2011). Evaluation of MycAssay™ *Aspergillus* molecular diagnostic test and automated EZ1 DNA extraction for detecting *Aspergillus* spp. DNA in bronchoalveolar samples of patients with risk factors for pulmonary invasive aspergillosis. Clinical Microbiology and Infection 17, S568–S569. P1942. http://dx.doi.org/10.1111/j.1469-0691.2011.03558.x

293. Srebro D et al. (2011). Diagnosis of invasive fungal infection by detection of early laboratory biomarkers in a child with anemia aplastica. Mycoses 54, 103. http://dx.doi.org/10.1111/ j.1439-0507.2011.02092.x

294. Sulahian A et al. (2011). Evaluation of the (1→3) β-D glucan assay (Fungitell™) in comparison with Platelia™ *Aspergillus* for the follow-up of invasive aspergillosis under treatment. Mycoses 54, 87. http://dx.doi.org/10.1111/j.1439-0507.2011.02092.x

295. Virginia R et al. (2011). Galactomannan determination in children: is there a real influence of nutrition? Mycoses 54, 88–89. http://dx.doi.org/10.1111/j.1439-0507.2011.02092.x

296. Bougnoux ME et al. (2010). Saccharose-stabilized intravenous immune globulin as a cause of false-positive *Aspergillus* galactomannan assay in patients. Clinical Microbiology and Infection 16, S518. P1759. http://dx.doi.org/10.1111/j.1469-0691.2010.03239.x

297. Banon R et al. (2009). Evaluation of serum *Aspergillus* galactomannan in haematological patients. Clinical Microbiology and Infection 15, S234. P907. http://dx.doi.org/10.1111/j.1469-0691.2009.02858.x

298. Tsagarakis N et al. (2009). Anti-*Aspergillus* antibodies and galactomannan antigen detection for serodiagnosis of aspergillosis. Clinical Microbiology and Infection 15, S234. P905. http://dx.doi.org/10.1111/j.1469-0691.2009.02858.x

© 2026 Bio-Rad Laboratories, Inc.

Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. Platelia is a trademark of Bio-Rad Europe GmbH in certain jurisdictions. All trademarks used herein are the property of their respective owner. © 2026 Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

Clinical Diagnostics Group

Website www.bio-rad.com/diagnostics **U.S.** 1 800 224 6723 **Australia** 61 2 9914 2800 **Austria** 00 800 00 24 67 23 **Belgium** 00 800 00 24 67 23 **Brazil** 55 11 3065 7550 **Canada** 1 800 361 1808 **China** +86 21 6169 8500 **Czech Republic** 00 800 00 24 67 23 **Denmark** 00 800 00 24 67 23 **Finland** 00 800 00 24 67 23 **France** 00 800 00 24 67 23 **Germany** 00 800 00 24 67 23 **Greece** 30 210 7774396 **Hong Kong** 852 2789 3300 **Hungary** 00 800 00 24 67 23 **India** 91 124 4029300 **Israel** 00 800 00 24 67 23 **Italy** 00 800 00 24 67 23 **Japan** 81 3 6361 7070 **Luxembourg** 00 800 00 24 67 23 **Mexico** 52 55 5488 7670 **The Netherlands** 00 800 00 24 67 23 **New Zealand** 64 9415 2280 **Norway** 00 800 00 24 67 23 **Poland** 00 800 00 24 67 23 **Portugal** 00 800 00 24 67 23 **Republic of Korea** 82 080 007 7373 **Russia** 7 495 721 14 04 **Singapore** 65 6415 3170 **South Africa** 27 11 442 8508 **Spain** 00 800 00 24 67 23 **Sweden** 00 800 00 24 67 23 **Switzerland** 00 800 00 24 67 23 **Taiwan** 886 2 2578-7189 **Thailand** 662 651 8311 **United Arab Emirates** 971 4 818 7300 **United Kingdom** 00 800 00 24 67 23